The purpose of the study is to understand how these treatments impact the physical health-related quality of life for individuals experiencing PASC. Participants will be randomly assigned to receive either Metformin, Colchicine, or a placebo. The study will last for a period of 12 weeks, during which participants will take the assigned treatment orally in tablet form. The maximum daily dose for Metformin is 1500 mg, and for Colchicine, it is 1 mg. The study will monitor the participants’ health and any changes in their symptoms throughout this period.

At the end of the 12 weeks, the study will assess the participants’ physical health using a standardized questionnaire. This will help determine if the treatments have improved their quality of life. The study will also look at other aspects of health, such as mental well-being and the ability to perform daily activities. The findings from this trial could provide valuable insights into managing the long-term effects of COVID-19.

The purpose of the research is to compare brain activity and structure, as well as immune‑related blood findings, between people with ongoing symptoms and those who have recovered fully. Participants will have a brief blood draw, undergo a scan that measures cellular energy use using PET, and receive a detailed brain scan with MRI that shows both structure and function. After the imaging sessions, individuals will complete questionnaires about the presence and severity of their symptoms. The study follows a straightforward schedule of these visits over several weeks, without any additional experimental treatments.

During the study, participants receive flutemetamol (18F) and then undergo a PET scan, which is an imaging test that shows where the tracer goes in the body. Some participants may also have a MRI scan, which uses magnetic fields to create pictures of the brain. Blood samples and symptom questionnaires are also used to gather more information about the amount of microclots and the presence and severity of symptoms.

The study is expected to run over several months. It focuses on whether this imaging method can show differences in amyloid-containing microclots between people with post-COVID syndrome and controls, and whether these findings relate to symptoms and brain scan results.

The purpose of the study is to find out if fluvoxamine treatment, given at doses between 50 and 200 milligrams per day, leads to lower levels of fatigue compared to placebo after 13 weeks of treatment. Fluvoxamine is a medication that affects certain chemical messengers in the brain, particularly one called serotonin. During the study, participants will take either fluvoxamine or placebo by mouth for about 13 weeks. The study will measure how severe the fatigue is, how well people can think and concentrate, and how their overall quality of life is affected.

The study will also look at other symptoms that can occur after COVID-19, such as the worsening of symptoms after activity and problems with heart rate changes when standing. Researchers will collect blood samples to measure various substances in the body that might be related to inflammation and other biological processes. Some participants may also have the option to take part in a smaller additional study that uses Magnetic Resonance Imaging, a type of scan that creates detailed pictures of the brain, to see how blood flow and brain activity might be affected in people with post COVID symptoms. The study will also track any side effects that participants might experience from the medication.

The main aim of the trial is to find out whether bupropion can reduce the level of fatigue and improve physical functioning in people with this condition. Participants are assigned by chance to receive either the active drug or the placebo, take the study tablets for about eight weeks, and attend a few clinic visits: one at the start, one midway through treatment, one at the end of the eight‑week period, and a follow‑up about four weeks later. During these visits, simple questionnaires and short physical tests are completed.

The questionnaires include the Fatigue Severity Scale, which asks the participant to rate how often they feel exhausted during daily activities, and the Short Form-36 Physical Function, which measures how easy it is to perform common tasks such as walking or climbing stairs. Additional brief surveys evaluate mood, anxiety and breathing difficulty, while a quick sit‑to‑stand test checks basic exercise capacity. All assessments are designed to be easy to understand and complete.

During the study, the effects of these treatments will be observed across various areas of health, such as fatigue, breathing, memory, thinking, communication, muscles, joints, and circulation. The course of the study involves monitoring changes in these symptoms over time. Additionally, researchers will look at blood biomarkers, which are natural substances found in the blood that can indicate how the body is functioning, as well as plasma proteomics and plasma metabolomics, which are specialized tests used to study proteins and metabolites to understand the biological processes occurring in the body.

The purpose of the study is to see if Sonlicromanol can reduce the severe tiredness that people with long COVID experience after 13 weeks of treatment. The medicine is taken by mouth and the highest daily amount given will be 180 milligrams. The treatment period will last for 13 weeks, which is about three months.

During the study, participants will be checked at different times to see how they are doing. The main focus will be on measuring tiredness levels at week 13 using a specific questionnaire. The study will also look at other aspects of health including overall quality of life, thinking abilities, and physical strength. These measurements will be done at the start of the study and then again at weeks 4, 8, and 13 using various questionnaires and physical tests such as grip strength measurements and thinking tests. The study is designed so that neither the participants nor the doctors know who is receiving the actual medicine and who is receiving the placebo until the study is finished.

The purpose of this study is to find out if bevacizumab can improve the lung’s ability to transfer oxygen in patients with long COVID who have impaired lung function. The study will measure whether there is an improvement in this lung function test within three months after receiving the first bevacizumab treatment. The medication will be given over a treatment period of up to two months, and patients will be followed for seven months in total to see how their symptoms and lung function change over time.

During the study, patients will have their breathing ability and lung function checked at different time points after starting bevacizumab treatment. The study will also look at various symptoms such as shortness of breath, fatigue, and other effects that long COVID can have on daily life, mental health, and thinking abilities. Blood samples will be collected to measure certain substances in the blood that are related to blood vessel growth. The study will also keep track of any unwanted effects from the medication and whether patients need any medical care during the seven-month follow-up period.

The purpose of the study is to evaluate how well EGb 761® works compared to a placebo in improving cognitive function in individuals with cognitive impairment due to post-COVID-19 syndrome. Participants in the study will be randomly assigned to receive either the Ginkgo biloba extract or a placebo. The study will last for 12 weeks, during which participants will take the tablets daily. Throughout the study, participants will undergo various tests to assess changes in their cognitive abilities, such as memory and attention, as well as their overall well-being.

Participants will be monitored for any side effects or adverse reactions to the treatment. The study aims to provide valuable information on whether Ginkgo biloba extract can help improve cognitive function in those affected by post-COVID-19 syndrome. This research could potentially lead to new treatment options for individuals experiencing long-term cognitive issues after recovering from COVID-19.

The purpose of the study is to determine if there is more fibroblast activity in patients who continue to have symptoms compared to those whose symptoms have resolved. Participants will receive an injection of a solution containing [68Ga]FAPI-46, which helps highlight fibroblast activity during the imaging process. The study will compare the results between different groups of patients, including those with ongoing symptoms and those who have recovered.

Throughout the study, participants will undergo the PET/CT scan and may be asked to complete questionnaires about their health and symptoms. The study aims to provide a better understanding of how long COVID affects the lungs and to explore potential ways to personalize diagnosis and treatment for affected individuals. The study is expected to continue until early 2026.

During the study, participants will receive either plitidepsin or placebo along with several supportive medications including palonosetron, famotidine, dexamethasone phosphate, and dexchlorpheniramine. These additional medications help manage potential side effects of the treatment. The study will last for 90 days after treatment, during which participants’ overall health and symptoms will be monitored.

Throughout the study, various aspects of participants’ health will be evaluated, including physical activity levels, mental health, sleep quality, and general well-being. The researchers will also examine blood samples to study changes in inflammation markers and immune system responses. This comprehensive approach will help determine how well the treatment works for people with Post-COVID-19 Condition.

The study compares tianeptine with placebo to determine if the medication can help improve cognitive function in patients experiencing COVID fog symptoms. The treatment involves taking tianeptine tablets by mouth, with a maximum daily dose of 37.5 mg over a period of 16 weeks. During the study, researchers will monitor changes in thinking abilities, memory, and other mental functions.

The research also aims to understand how COVID fog develops by examining brain function through various tests, including positron emission tomography (PET scan, a specialized imaging technique that shows how the brain is working). The study will track improvements in cognitive function, mood, sleep, and overall well-being throughout the treatment period.

The purpose of this study is to determine how well pregabalin and complex rehabilitation help reduce fatigue symptoms in people who have experienced persistent tiredness for at least 6 months after having COVID-19. The study will measure changes in fatigue levels and physical abilities, including how far participants can walk.

During the study, participants will take either pregabalin tablets or placebo tablets. The maximum daily dose of pregabalin will be 300 mg. The study will last for 6 months, during which various aspects of participants’ health will be monitored, including their energy levels, walking ability, quality of life, sleep patterns, and emotional well-being. Regular assessments will be conducted to track participants’ progress throughout the study period.

The study will test different doses of Vericiguat tablets compared to placebo in adults who have been experiencing post-COVID symptoms for 6 months or longer. Participants will take the medication orally, with doses ranging from 2.5 mg to 10 mg per day. The treatment period will last for 10 weeks.

During the study, researchers will measure changes in physical function using a standardized health survey. They will also monitor other aspects of health, including fatigue levels and muscle strength. The study will track any side effects that participants may experience during the treatment period.

The purpose of the study is to compare the effects of IMU-838 with a control group on the overall physical function of patients by Day 56. Participants in the study will receive either the IMU-838 tablets or a placebo, which looks like the real medication but does not contain the active ingredient. The study will last for several weeks, during which participants will take the medication and have their physical and mental health monitored at different intervals.

Throughout the study, participants will be asked to report on their symptoms and any changes they experience. The trial aims to gather information on how IMU-838 affects symptoms like fatigue, cognitive impairment, and shortness of breath, which are common in PCS. By the end of the study, researchers hope to determine if IMU-838 can be an effective treatment option for those suffering from PCS.

Participants in the study will receive anakinra, which is administered as a solution for injection. The study will compare the effects of taking anakinra for either four weeks or eight weeks. Some participants will receive a placebo for part of the study period. The goal is to determine if a longer duration of anakinra treatment leads to better outcomes in terms of reducing symptoms and improving lung function.

The trial will last between four to eight weeks, during which various health indicators will be monitored. These include changes in lung function, immune response, and overall physical performance, such as the distance walked in a six-minute walk test. The safety of anakinra will also be closely observed throughout the study.

The purpose of the study is to compare the effects of methylprednisolone with a placebo in improving memory satisfaction over an eight-week period. Participants will be randomly assigned to receive either the medication or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a “double-blind” study. The treatment will be administered in the form of tablets taken orally. The study will last for a total of 12 weeks, with regular assessments to monitor changes in memory and cognitive function.

Throughout the study, participants will undergo various assessments to evaluate their memory and cognitive abilities. These assessments will help determine if there is an improvement in memory satisfaction and other cognitive functions from the start of the study to the end of the treatment period. The study aims to provide valuable insights into the potential benefits of methylprednisolone for individuals suffering from cognitive deficits due to Post COVID-19 Syndrome.

Participants in the study will receive either Plitidepsin or a placebo, which is a substance with no active medication. The study will compare the effects of Plitidepsin to the placebo to see if there is an improvement in the participants’ ability to perform daily activities. The study will also monitor any side effects that may occur. Other medications involved in the study include Famotidine, Dexamethasone Phosphate, Dexchlorpheniramine, and Palonosetron, which are used for various supportive treatments such as managing nausea, vomiting, and allergic reactions.

The study will take place over a period of time, with participants receiving treatments and being monitored for changes in their condition. The goal is to see if there is an improvement in symptoms and overall quality of life. Participants will be assessed at different intervals to track their progress and any changes in their health status. The study aims to provide valuable information on the potential benefits of Plitidepsin for those suffering from Post COVID-19 condition.